

Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: Results of the TRIAGE study

On behalf of the TRIAGE study Investigators

*TRIAGE Patients Undergoing Percutaneous Coronary Interventions
To Improve Clinical Outcomes Through Optimal Platelet Inhibition*

SCAI 2015 | San Diego | 8 May 2015

Disclosures

- *The presenting author has no financial conflicts to disclose*

STUDY ORGANIZATION

Multicenter prospective observational study



LEADERSHIP

George Dangas (PI)

Mount Sinai Medical Center

DATA MANAGEMENT

Roxana Mehran

Usman Baber

Jaya Chandrasekhar

Melissa Aquino

Samantha Sartori

Icahn School of Medicine at Mount Sinai

SPONSOR

Eli-Lilli and Daiichi-Sankyo

SITE PIs

Annapoorna Kini

Mount Sinai Medical Center,
New York

Richard Schlofmitz

St. Francis, New York

Bernard Witzenbichler

Carsten Skurk

Charité University Hospital,
Berlin

BACKGROUND

- High on treatment platelet reactivity (HTPR) is associated with greater incidence of adverse cardiac events
- Platelet function testing alone for thienopyridine selection after PCI has not been shown to correlate with improved outcomes in randomized trials
- The role of platelet function testing *in the context of clinical risks* has not been investigated

STUDY OBJECTIVE

Compare outcomes in patients treated with prasugrel vs. clopidogrel at PCI following determination of platelet reactivity in conjunction with clinical risks:

- *Primary Efficacy Endpoint at 1 year*
 - **MACE** = composite of death, non-fatal MI, definite or probable stent thrombosis
- *Primary Safety Endpoint at 1 year*
 - **Bleeding** = BARC 2, 3 or 5

STUDY DESIGN

- Multicenter prospective observational study conducted over 3 sites from March 2012 to December 2014
- **Main inclusion criterion:** Chronic clopidogrel therapy for at least 2 weeks prior to elective or urgent PCI
- **Main exclusion criterion:** Cardiogenic shock
- Sample Size Assumption – 1 year MACE rate ~ 14% and a relative risk reduction with prasugrel ~ 40%, requiring 1000 patients. However due to slow enrollment, recruitment was terminated at 318 patients

METHODS

- PRU tested in the cath lab immediately prior to PCI with the VerifyNow assay.
- $HTPR = PRU \geq 230$.
- Based on the study algorithm, treatment was continued with Clopidogrel or switched to Prasugrel (LD of 30 or 60mg).
- Follow up was by telephone at 1,6,12 months.
- Events were independently adjudicated.

STUDY ALGORITHM

- High ischemic risk was defined as any of the following criteria
 - a. PCI for ACS or stent thrombosis
 - b. High angiographic risk PCI (LM/Bifurcation PCI, ≥ 4 stents, thrombotic lesions)
 - c. 30 day stent thrombosis score of $\geq 6^*$

- High bleeding risk was defined as any of the following criteria
 - a. Bleeding risk score $\geq 10^\#$
 - b. Recent surgery
 - c. Recent bleeding history
 - d. Bleeding diathesis

STUDY ALGORITHM

PRU tested in the cath lab prior to PCI

PRU \geq 230 = HTPR

PRU $<$ 230 = LTPR

Group 2 - Age $<$ 75y, Weight \geq 60kg, No stroke/TIA/malignancy

Group 1 - Age \geq 75y, Weight $<$ 60kg, Previous stroke/TIA, malignancy

Clopidogrel 75mg

HIGH ISCHEMIC RISK

**Clopidogrel 75mg
Or Prasugrel 5mg**

Yes

No

HIGH BLEEDING RISK

HIGH BLEEDING RISK

PRU = P2Y12 reactivity units

HTPR = High on treatment platelet reactivity

LTPR = Low on treatment platelet reactivity

Yes

No

Yes

No

Prasugrel 5mg


Prasugrel 10mg

**Clopidogrel 75mg
Or Prasugrel 5mg**

Prasugrel 10mg

OVERALL COHORT


Mean age of 65.9 (9.8) years and 19.0% women.



*40% patients at high ischemic risk by study criteria,
58% patients with PRU \geq 230 and/or high ischemic risk by
study criteria;*

34% patients at high bleeding risk by study criteria

72% received Clopidogrel, 28% received Prasugrel



BASELINE CHARACTERISTICS



	Clopidogrel N = 228	Prasugrel N = 90	p
Age, mean (SD)	66.5 ±9.9	64.4 ± 9.3	0.06
Female gender, n (%)	40 (17.5)	20 (22.2)	0.21
Hypertension	208 (91.2)	84 (93.3)	0.62
Diabetes Mellitus	91 (39.9)	47 (52.2)	0.12
Dyslipidemia	198(86.8)	84 (93.3)	0.14
Prior MI	69 (30.3)	38 (42.2)	0.06
Prior PCI, n (%)	199 (87.3)	81 (90.0)	0.5
Prior CABG, n (%)	43 (18.9)	24 (26.7)	0.12
CKD, n (%)	22 (9.6)	7 (7.8)	0.77
Current smoker, n (%)	39 (17.1)	8 (8.9)	0.04
Heart failure, n (%)	14 (6.1)	12 (13.3)	0.04
BMI, mean (SD)	28.2 ±4.6	30.2 ±6.3	0.002
Prior stroke, n (%)	19 (8.3)	0 (0.0)	0.005
Baseline PRU, mean (SD)	148.9 ±76	290.1 ±48	<0.0001



PROCEDURAL CHARACTERISTICS


	Clopidogrel N = 228	Prasugrel N = 90	p
Multivessel disease, n (%)	166 (72.8)	67 (74.5)	0.87
Left main disease, n (%)	32 (14.4)	13 (14.0)	0.92
Stent thrombosis, n (%)	1 (0.4)	4 (4.4)	0.01
Femoral access, n (%)	219 (96.1)	87 (96.7)	0.77
Vascular closure device, n (%)	210 (92.1)	87 (96.7)	0.28
No. of vessels treated, mean (SD)	1.2 ± 0.5	1.3 ± 0.4	0.26
No. of lesions treated, mean (SD)	1.7 ± 0.9	1.6 ± 0.8	0.73
No. of stents implanted, mean (SD)	1.7 ± 0.98	1.6 ± 0.8	0.14
Total stent length, mm, mean (SD)	34.8 ± 23.6	31.9 ± 23.7	0.33
Stent type used: DES only, n (%)	217 (95.2)	83 (92.2)	0.28
Procedural anti-thrombotic therapy			
Heparin, n (%)	62 (27.2)	16 (17.8)	0.08
Bivalirudin, n (%)	109 (47.8)	67 (74.4)	<0.0001
Glycoprotein IIb/IIIa inhibitor, n (%)	8 (3.5)	2 (2.2)	0.55

1 YEAR CLINICAL OUTCOMES

	Clopidogrel N = 228	Prasugrel N = 90	p
Ischemic outcomes*			
Death/Non-fatal MI/ST	8 (3.5)	4 (4.4)	0.70
Death	4 (1.8)	4 (4.4)	0.17
Non-fatal MI	5 (2.2)	1 (1.1)	0.52
Stent thrombosis	1 (0.4)	0 (0.0)	0.53
Clinically driven TVR	16 (7.0)	6 (6.7)	0.88
Death/Non-fatal MI/ST/TVR	22 (9.7)	10 (11.1)	0.73
Bleeding outcomes*			
BARC 2, 3 or 5	18 (7.9)	5 (5.6)	0.47
BARC 3 or 5	10 (4.4)	1 (1.1)	0.15
Any BARC bleed	32 (14.0)	8 (8.9)	0.21
TIMI Major	10 (4.4)	1 (1.1)	0.15
ACUITY Major	11 (4.8)	1 (1.1)	0.21

*Numbers are presented as n (%)

Primary efficacy endpoint: MACE (Death, Non-fatal MI, ST)




Number at risk

Clopidogrel	228	226	225	223	220
Prasugrel	90	89	89	89	86


— Clopidogrel — Prasugrel



Secondary Ischemic Endpoints



Primary Safety Endpoint: BARC bleeding 2,3 or 5




Number at risk


Clopidogrel	228	221	216	214	210
Prasugrel	90	88	87	85	85

— Clopidogrel — Prasugrel

Secondary Bleeding Endpoints



PRU Cut-off 230: MACE (Death, Non-fatal MI, ST)



Number at risk


	0	30	90	180	365
PRU < 230	212	211	210	208	206
PRU ≥ 230	106	104	104	104	100

— PRU < 230


— PRU ≥ 230



PRU Cut-off 230: Secondary Ischemic Endpoints



PRU Cut-off 208: MACE (Death, Non-fatal MI, ST)



Number at risk


PRU < 208	185	184	183	182	181
PRU ≥ 208	133	131	131	130	125

— PRU < 208

— PRU ≥ 208



PRU Cut-off 208: Secondary Ischemic Endpoints



CONCLUSIONS

- Use of a clinical risk algorithm to triage real-world PCI patients for choice and intensity of thienopyridine prescription resulted in similar ischemic outcomes in HTPR patients receiving prasugrel and primarily LTPR patients on clopidogrel.
- There was no untoward increase in bleeding with prasugrel compared with clopidogrel.

LIMITATIONS

- Low enrollment, underpowered study – precluding definitive conclusions.
- Observational design, unblinded prescription of therapy.
- Low event rate for the primary endpoint despite an all-comer high-risk population – predominant 2nd gen. DES use.
- Use of an unvalidated study treatment algorithm - albeit incorporating ischemic and bleeding risk scores validated in ACS.

IMPLICATIONS

- When Prasugrel is prescribed to carefully selected ACS and non-ACS PCI patients, there is no untoward increase in bleeding
- Use of platelet function testing may identify more patients at a high ischemic risk, than clinical assessment alone
- The best PRU cut-off for HTPR in a real world unselected population for risk-prognostication is undetermined
- The effect of a tailored integrated assessment for thienopyridine prescription needs randomized examination in future trials

Thank you to all the investigators and the site and study teams



St. Francis Hospital	Marie Grgas
Charité University Hospital	Birgitt Blank
Mount Sinai Medical Center	Tami Williams Omar Meelu Juliana Laze
Icahn School of Medicine at Mount Sinai	Jennifer Yu Susan Mahoney Kristin Falciglia Jin Young Cha

